Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region
about
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virusMore tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimersT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingPeptide length determines the outcome of TCR/peptide-MHCI engagementLack of heterologous cross-reactivity towards HLA-A*02:01 restricted viral epitopes is underpinned by distinct αβT cell receptor signaturesPeptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition.Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes.Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionEngineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery.Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRsProperties and applications of single-chain major histocompatibility complex class I molecules.Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors.Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus.Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers.High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.Coreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide-MHC.Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers.Targeted suppression of autoreactive CD8(+) T-cell activation using blocking anti-CD8 antibodies.Tricks with tetramers: how to get the most from multimeric peptide-MHC.CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold.Immunoinformatics and modeling perspective of T cell epitope-based cancer immunotherapy: a holistic picture.MHC-peptide tetramers for the analysis of antigen-specific T cells.The molecular determinants of CD8 co-receptor function.Functional avidity: a measure to predict the efficacy of effector T cells?Co-Receptor CD8-Mediated Modulation of T-Cell Receptor Functional Sensitivity and Epitope Recognition Degeneracy.Targeting Hsp70: A possible therapy for cancer.Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells.Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8+ T cells by flow cytometry.CD8 controls T cell cross-reactivity.Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity.MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry.Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition.Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.
P2860
Q24645078-AB1A97F5-B203-4541-A0B1-1449D3076084Q26864749-7BCDC125-F187-4E9C-951D-CB82117CCCF8Q27672418-137676C8-6483-47EB-A270-3E7ADDCAEB7AQ27675544-B572B790-C9A1-4E37-A1C5-05EC452B7CEAQ27728085-EEDA617F-A6FC-4440-A99F-1EBF79C55B95Q30351955-E5278C04-DBF6-490B-9C09-4329410B316BQ33568699-A28B26A5-33EE-4F7B-9861-AECB4D6B5CC9Q33635226-05600EF0-718A-4CA7-9B70-F0519ACC64DAQ33698112-2748A398-FC3E-4ACC-99FC-F6202FB840F2Q33871399-89327D39-E931-4E39-BABF-13FDF1003D72Q34137733-1D4DC174-8F56-4EBC-8ABE-4BCA58F38F81Q34756907-651AA00B-7BD4-4F07-A028-2A3AE2E8E17BQ35075017-90CA02E8-FF49-466B-BC7B-44132EA78A77Q35132238-DE2FB721-DDFD-4231-A908-4C8148037882Q35914856-9533DE01-C249-4422-A834-0A2776299715Q36777192-94C4CA25-BA3B-4BA0-9FE3-17862B10EDEEQ36980391-83FB04A5-5DA8-4043-A0D8-A7A8C244F48EQ37119914-20A0E507-2F05-46A8-BEA3-D6D92026782BQ37125754-EEA595FA-E696-4429-83FB-3040739DDA61Q37272398-4BEDE8A8-BD2A-4C27-82FC-A6063891FBFCQ37342952-5166BDFD-3DFB-47D1-9FF3-81C6696794FFQ37363261-B2AB31B4-2A4C-4E8F-96D5-CC0E6902019AQ37560213-3DC53F18-D3E9-40A5-8437-DE753249CA13Q37606469-241A7AE4-EDA6-4849-93B1-EB49F0D9CD01Q37771944-5ADBCD37-A150-4278-BD20-0FA7C72D3B77Q38026943-9B4E68DE-312D-4630-8BAA-38312A4AD141Q38066211-63DB5067-8FDC-438E-9D9C-2A2D80D4D9B6Q38154887-E57BD96A-77A4-42D3-AD16-3794A9A39A8BQ38742944-E9408EBE-32CF-41DC-8919-499A523AB338Q38763198-5F27A148-F216-4BCA-BCD4-61BE93EDDA31Q38902980-E39A9667-49B1-4157-8947-E15AC49B6279Q39655504-E10176C8-EBFC-4841-83F0-B17992E39605Q40898202-FC28FC50-5B0E-48B6-8A5B-A59931EE6BFDQ41955439-84080C26-40EC-4471-B484-A5AE62B3FBE0Q52727193-D4B2C6DD-F94E-44EC-911E-B34A2B34156AQ52730243-87386C2F-558D-4E3B-B119-9209CF449184Q55002157-8C34ACA3-C864-4934-B8B2-B278FD3246B3Q55715332-46183BBE-FCCE-44B7-BD11-71E87023BA49
P2860
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Enhanced immunogenicity of CTL ...... g MHC class I invariant region
@en
type
label
Enhanced immunogenicity of CTL ...... g MHC class I invariant region
@en
prefLabel
Enhanced immunogenicity of CTL ...... g MHC class I invariant region
@en
P2093
P2860
P50
P356
P1476
Enhanced immunogenicity of CTL ...... g MHC class I invariant region
@en
P2093
Anna Lissina
Bruno Laugel
Emma Gostick
Fareed Mirza
Hugo A van den Berg
Jonathan M Boulter
Jonathan Vernazza
Linda Wooldridge
Meir Glick
P Rod Dunbar
P2860
P304
P356
10.1002/EJI.200636765
P407
P577
2007-05-01T00:00:00Z